The mean nondisplaceable binding potential was lower in the hippocampus, entorhinal cortex, and amygdala in AD patients than in controls, supporting 5‐HT1A receptor PET as a tool for the assessment of early neurodegenerative changes in AD. This evidence concerns the gene HTR1A and Alzheimer disease.